Lymphoma Research Foundation
MENU

DONATELEARN
LEARNDONATE


For Patients and Caregivers
About Lymphoma
Treatment Options
Resources & Support
For Healthcare Professionals
For Researchers
About LRF
About Us
Our Impact
Our Scientific Experts
25 Years of Innovation and Progress
Support LRF
Team LRF - Walks, Ride, DIY
Ticketed Events
Volunteer
Other Ways to Give
Subscribe
  • Latest News
Home » Lymphoma News » Page 4
Lymphoma News

U.S. Food and Drug Administration Approves Biosimilar Rituximab-pvvr (Ruxience) for CD20-positive non-Hodgkin B-cell Lymphomas and Chronic Lymphocytic Leukemia

On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab

Read More >
Lymphoma News

U.S. Food and Drug Administration Approves Polatuzumab Vedotin-Piiq (Polivy) for Diffuse Large B-Cell Lymphoma

On June 10, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) for adult

Read More >
Lymphoma News

U.S. Food and Drug Administration Approves Chemo-Free Therapy for Relapsed/Refractory Indolent Lymphomas

On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with

Read More >
Lymphoma News

U.S. Food and Drug Administration Approves Ruxolitinib (JAKAFI) for Acute Graft-Versus-Host Disease

On May 24, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory acute

Read More >
Lymphoma News

FDA Approves Chemo-Free Frontline Regimen for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

New York (May 15, 2019) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of venetoclax (VENCLEXTA, AbbVie Inc. and

Read More >
Lymphoma News

ECHELON-2 Trial Demonstrates “Practice-Changing” Results for Peripheral T-Cell Lymphomas

ECHELON-2 is the first study in patients with PTCL to show an improvement in overall survival over a standard therapy such as CHOP

Read More >
Lymphoma News

FDA Approves Ibrutinib (IMBRUVICA) in Combination with Obinutuzumab (GAZYVA) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for

Read More >
Lymphoma News

U.S. Food and Drug Administration Approves Brentuximab Vedotin (ADCETRIS) for Frontline Treatment of Peripheral T-Cell Lymphoma (PTCL)

New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination

Read More >
Lymphoma News

In Memoriam: Paul Allen

The Lymphoma Research Foundation extends its heartfelt condolences to the family, loved ones and colleagues of Paul Allen.  Mr. Allen contributed greatly to science, philanthropy

Read More >
Lymphoma News

U.S. Food and Drug Administration Approves Duvelisib (COPIKTRA) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult

Read More >
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page»
 

Stay informed with news, alerts and other resources.

   Please leave this field empty

Stay informed with news, alerts and other resources.





   Please leave this field empty



  • Start A Fundraiser

  • Download the LRF App

  • Become a Buddy

  • Attend an Event

  • Become an Advocate

  • Share Your Story

The Lymphoma Research Foundation’s mission is to eradicate lymphoma and serve those impacted by this blood cancer. LRF Helpline: 800-500-9976|HELPLINE@LYMPHOMA.ORG

The Lymphoma Research Foundation’s mission is to eradicate lymphoma and serve those impacted by this blood cancer. LRF Helpline: 800-500-9976 HELPLINE@LYMPHOMA.ORG

CONTACT US ›|CAREERS AT LRF ›

CONTACT US ›|CAREERS AT LRF ›

Privacy Policy|Donor Privacy Policy|Gift Acceptance Policy

© 2021 Lymphoma Research Foundation

Privacy Policy|Donor Privacy Policy|Gift Acceptance Policy

© 2021 Lymphoma Research Foundation